Finance

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

Published by Global Banking & Finance Review

Posted on February 24, 2026

1 min read

· Last updated: April 2, 2026

Add as preferred source on Google
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025
Global Banking & Finance Awards 2026 — Call for Entries

Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-

AstraZeneca Raises CEO Pascal Soriot's 2025 Pay to Nearly $24 Million

FTSE 100 Context

Total Pay and Year-over-Year Change

Soriot's 2025 Compensation Breakdown

Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a filing showed on Tuesday. 

Annual Bonus Increase

AstraZeneca, which is London's most valuable company and whose earnings jumped in 2025, paid Soriot 4.3 million pounds in annual bonus last year, up about 22% from 2024 levels, according to the company's annual report. 

Exchange Rate Used

($1 = 0.7415 pounds)

Reporting and Editing Credits

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

  • Pascal Soriot’s total 2025 pay increases 6.4% to £17.7m ($23.9m).
  • Annual bonus rises to £4.3m, about 22% higher than 2024.
  • Soriot remains among the FTSE 100’s top-paid executives.
  • AstraZeneca’s 2025 earnings improved, supporting the pay uptick.
  • Company cites higher annual bonuses as the key driver of the increase.

References

Frequently Asked Questions

What is the main topic?
AstraZeneca increased CEO Pascal Soriot’s 2025 compensation to £17.7m ($23.9m), a 6.4% rise from the prior year. The boost was led by a larger annual bonus.
How much did the annual bonus change?
Soriot’s annual bonus reached £4.3m for 2025, about 22% higher than in 2024, contributing significantly to the overall pay increase.
Why is this relevant to investors?
The pay rise reflects AstraZeneca’s stronger 2025 performance and ongoing executive-compensation debates in the FTSE 100, which can influence governance and sentiment.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category